Ludovicus Staelens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ludovicus Staelens has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Peter Blanckaert
Belgian Early Warning System Drugs, Scientific Institute of Public Health, Juliette Wytsmanstraat 14, 1050 Brussel, Belgium
3 shared publications - Bart Cornelissen
Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, the Netherlands.
2 shared publications Guido Slegers
Ghent University
2 shared publicationsKatia Vandenbulcke
Ghent University
2 shared publicationsRuth Oltenfreiter
Ghent University
2 shared publications- Veerle Kersemans
Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, United Kingdom
2 shared publications
Latest Publications
- 15 January 2007
- Vol. 51 (4) , 352-6
Iodine-123-interleukin-2 scintigraphy in metastatic hypernephroma: a pilot study.
This pilot study reports on the uptake of (123)I-interleukin 2 (IL-2) in metastatic renal cell carcinoma (MRCC) patients and its relationship to prognostic factors of response or failure of MRCC to cytokines treatment. Nine consecutive patients with MRCC underwent an (123)I-IL-2 scan (6 male and 3 female; mean age 64 years; range 51-78). Uptake in metastases was related to a summed score of 4 independent factors, predictive of rapid progression under cytokine treatment as defined by Negrier et al. Four patients presented with metastases at one site, 4 at 2 sites and one patient at 3 different sites. Summed scores were: 5 patients had a summed score of 1; 3 a summed score of 2 and 1 patient a summed score of 3. Uptake of (123)I-IL-2 by tumor tissue was found in only 2 patients. Uptake occurred in 1 patient with a summed score of 3 and in 1 with a summed score of 2. In this small series of patients with MRCC, (123)I-IL-2 uptake was found in tumors of 2 patients who less likely will benefit from cytokine treatment. Additional studies are needed to assess the relationship between the pretreatment uptake of (123)/I-IL2 in MRCC and the response to IL-2 therapy.
- 15 January 2007
- Vol. 51 (4) , 352-6
Iodine-123-interleukin-2 scintigraphy in metastatic hypernephroma: a pilot study.
This pilot study reports on the uptake of (123)I-interleukin 2 (IL-2) in metastatic renal cell carcinoma (MRCC) patients and its relationship to prognostic factors of response or failure of MRCC to cytokines treatment. Nine consecutive patients with MRCC underwent an (123)I-IL-2 scan (6 male and 3 female; mean age 64 years; range 51-78). Uptake in metastases was related to a summed score of 4 independent factors, predictive of rapid progression under cytokine treatment as defined by Negrier et al. Four patients presented with metastases at one site, 4 at 2 sites and one patient at 3 different sites. Summed scores were: 5 patients had a summed score of 1; 3 a summed score of 2 and 1 patient a summed score of 3. Uptake of (123)I-IL-2 by tumor tissue was found in only 2 patients. Uptake occurred in 1 patient with a summed score of 3 and in 1 with a summed score of 2. In this small series of patients with MRCC, (123)I-IL-2 uptake was found in tumors of 2 patients who less likely will benefit from cytokine treatment. Additional studies are needed to assess the relationship between the pretreatment uptake of (123)/I-IL2 in MRCC and the response to IL-2 therapy.
- 30 April 2005
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 32 (3) , 293-299
In vivo evaluation of [123I]-3-(4-iodobenzyl)-1,2,3,4-tetrahydro-8-hydroxychromeno[3,4-c]pyridin-5-one: a presumed dopamine D4 receptor ligand for SPECT studies
- 30 April 2005
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 32 (3) , 293-299
In vivo evaluation of [123I]-3-(4-iodobenzyl)-1,2,3,4-tetrahydro-8-hydroxychromeno[3,4-c]pyridin-5-one: a presumed dopamine D4 receptor ligand for SPECT studies
- 1 April 2005
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 78 (928) , 338-342
Comparison between 1 T MRI and non-MRI based volumetry in inoculated tumours in mice
Tumour volume is an important therapeutic endpoint for mouse tumour models in the evaluation of new chemotherapeutic drugs and in pre-clinical evaluation of new radioimmunotherapy pharmaceuticals. In this study, two 1 T MRI-based methods both using T1-T2 hybrid weighting, a manual method (determination of the area per slice) and a semi-automated method (using thresholding), are compared with two classical methods, the abovementioned calliper method and volumetry by water displacement after dissection of the tumour. Interoperator and intraoperator differences for both MRI-based methods were good (no differences p<0.05 using a repeated measures analysis of variance (ANOVA) test). Correlation between the different methods was excellent. No significant differences were obtained (p<0.05), except for the semi-automated method, because it automatically excludes necrotic regions from the tumour. Therefore, we conclude that both manual and semi-automated tumour volumetry in subcutaneous tumour bearing athymic mice by low-field MRI are accurate and reliable methods. The semi-automated method is especially useful for larger tumour volumes, since it accounts for necrotic areas within the tumour.
- 1 April 2005
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 78 (928) , 338-342
Comparison between 1 T MRI and non-MRI based volumetry in inoculated tumours in mice
Tumour volume is an important therapeutic endpoint for mouse tumour models in the evaluation of new chemotherapeutic drugs and in pre-clinical evaluation of new radioimmunotherapy pharmaceuticals. In this study, two 1 T MRI-based methods both using T1-T2 hybrid weighting, a manual method (determination of the area per slice) and a semi-automated method (using thresholding), are compared with two classical methods, the abovementioned calliper method and volumetry by water displacement after dissection of the tumour. Interoperator and intraoperator differences for both MRI-based methods were good (no differences p<0.05 using a repeated measures analysis of variance (ANOVA) test). Correlation between the different methods was excellent. No significant differences were obtained (p<0.05), except for the semi-automated method, because it automatically excludes necrotic regions from the tumour. Therefore, we conclude that both manual and semi-automated tumour volumetry in subcutaneous tumour bearing athymic mice by low-field MRI are accurate and reliable methods. The semi-automated method is especially useful for larger tumour volumes, since it accounts for necrotic areas within the tumour.
- 28 February 2005
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 32 (2) , 193-200
In vivo evaluation of [123I]-4-iodo-N-(4-(4-(2-methoxyphenyl)-piperazin-1-yl)butyl)-benzamide: a potential sigma receptor ligand for SPECT studies
- 28 February 2005
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 32 (2) , 193-200
In vivo evaluation of [123I]-4-iodo-N-(4-(4-(2-methoxyphenyl)-piperazin-1-yl)butyl)-benzamide: a potential sigma receptor ligand for SPECT studies
- 29 December 2004
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 48 (2) , 101-108
Synthesis of [123I]‐3‐(4‐iodobenzyl)‐1,2,3,4‐tetrahydro‐8‐hydroxychromeno[3,4‐c]pyridin‐5‐one, a potential dopamine D4 ligand for SPECT studies
Schizophrenia is a devastating mental disorder characterized by relapsing psychotic episodes accompanied with emotional, professional and social decline. The classical dopamine hypothesis of schizophrenia postulates that hyperactivity of dopaminergic neurotransmission is responsible for the positive symptoms of the disorder, more exactly hyperactivity of the dopamine D2‐like receptors. One of these receptors is the D4 receptor which is thought to be involved in the motor side‐effects caused antipsychotics. However, research into the specific role of this receptor has been hampered by the lack of specific ligands. Therefore, a new 123I‐labelled compound was developed which may allow in vivo visualization of the D4 receptor by SPECT. [123I]‐3‐(4‐iodobenzyl)‐1,2,3,4‐tetrahydro‐8‐hydroxychromeno[3,4‐c]pyridin‐5‐one was prepared by electrophillic aromatic substitution of the tributylstannyl derivative. The radiochemical yield was 68±3% (n=5) and the specific activity was >2.96 Ci/µmol. Copyright © 2005 John Wiley & Sons, Ltd.
- 29 December 2004
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 48 (2) , 101-108
Synthesis of [123I]‐3‐(4‐iodobenzyl)‐1,2,3,4‐tetrahydro‐8‐hydroxychromeno[3,4‐c]pyridin‐5‐one, a potential dopamine D4 ligand for SPECT studies
Schizophrenia is a devastating mental disorder characterized by relapsing psychotic episodes accompanied with emotional, professional and social decline. The classical dopamine hypothesis of schizophrenia postulates that hyperactivity of dopaminergic neurotransmission is responsible for the positive symptoms of the disorder, more exactly hyperactivity of the dopamine D2‐like receptors. One of these receptors is the D4 receptor which is thought to be involved in the motor side‐effects caused antipsychotics. However, research into the specific role of this receptor has been hampered by the lack of specific ligands. Therefore, a new 123I‐labelled compound was developed which may allow in vivo visualization of the D4 receptor by SPECT. [123I]‐3‐(4‐iodobenzyl)‐1,2,3,4‐tetrahydro‐8‐hydroxychromeno[3,4‐c]pyridin‐5‐one was prepared by electrophillic aromatic substitution of the tributylstannyl derivative. The radiochemical yield was 68±3% (n=5) and the specific activity was >2.96 Ci/µmol. Copyright © 2005 John Wiley & Sons, Ltd.